Friday, 16 October 2026European Markets

ODFJELL TECHNOLOGY Stock Is 27% Up In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of ODFJELL TECHNOLOGY (Oslo Børs All-share Index_GI: OTL.OL) rose by a staggering 27.41% in 21 sessions from $28.53 to $36.35 at 13:47 EST on Monday, following the last session's upward trend. Oslo Børs All-share Index_GI is sliding 0.89% to $1,365.78, after consecutive sessions in a row of losses.

ODFJELL TECHNOLOGY's last close was $36.50, 13.34% below its 52-week high of $42.12.

About ODFJELL TECHNOLOGY

Odfjell Technology Ltd., a technology and engineering company, provides well, drilling, and engineering services in Norway, Europe, the Middle East, Asia, and the United Kingdom. It offers tubular and casing running, drilling tool rental, fishing, wellbore clean-up, and casing while drilling services; crew for drilling and maintenance on fixed or floating platforms; smart circulation tools; downhole tools; wired drill pipes; integrated solutions for plug and abandonment markets; and maintenance and recertification services for drilling equipment. The company also provides upgrades and modifications of drilling units; special periodic surveys; rig recertifications; yard stays; engineering and project management; marine and operability analysis; offshore execution, installation, and construction; energy mapping and reduction; and inspection and integrity management services. It serves oil and gas and oil service companies, and rig owners. The company was founded in 1973 and is based in Aberdeen, the United Kingdom. As of March 31, 2022, Odfjell Technology Ltd. operates as a stand alone company.

Volume

Today's last reported volume for ODFJELL TECHNOLOGY is 74707 which is 29.25% below its average volume of 105600.

More news about ODFJELL TECHNOLOGY (OTL.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com